Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
about
Tumor and stromal-based contributions to head and neck squamous cell carcinoma invasionCurrent role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinomaCIViC databaseFrequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for TreatmentClinical update on cancer: molecular oncology of head and neck cancerTargeting secondary immune responses to cetuximab: CD137 and the outside story.Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significanceThe role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014Cetuximab concomitant with second-line radiation therapy in patients with locally advanced recurrent squamous cell head and neck cancer.Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomasUnraveling the molecular genetics of head and neck cancer through genome-wide approachesGenomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.Xenograft assessment of predictive biomarkers for standard head and neck cancer therapiesTargeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.Epidermal Growth Factor Receptor Expression in Spindle Cell Carcinomas of the Head and Neck.Antiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neck.miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted TherapiesGenomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer.Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab.Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.Systemic therapy strategies for head-neck carcinomas: Current statusTargeting epidermal growth factor receptor for head and neck squamous cell carcinoma: still lost in translation?The molecular pathogenesis of head and neck squamous cell carcinomaMolecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibitionCetuximab: its unique place in head and neck cancer treatmentGenetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib.A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular binsMolecular profiling of head and neck squamous cell carcinoma.MERTK as a novel therapeutic target in head and neck cancer.Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancerEpidermal growth factor receptor inhibitor therapy for recurrent respiratory papillomatosis.The emerging era of personalized therapy in squamous cell carcinoma of the head and neck.Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
P2860
Q26825164-C905CBE3-3DB9-482B-ABF8-0993C03ED559Q26991953-EA85CA1F-3F4B-460C-8E45-D4C8CDFCD49AQ27612411-4DCC97FC-1A6E-4699-94E1-E7792B97E457Q27853169-E3D120B8-B141-4163-8E38-D676D6798A70Q28079309-1A3206AD-524A-4808-BA15-24F66070947DQ33601653-10E3D483-698D-4FED-BA4A-D67D133C7D4CQ33607965-1ACEDA6B-E0A9-44B9-9AC7-7753BBF9A5F3Q33695197-23664BA0-4F13-4636-8D3F-91FC5973A161Q33872496-1D94B3F8-3E8C-4B5B-BB1A-C90228A31BD2Q33898889-0E82DDC9-2326-4764-B399-3CD32793D927Q33924908-01E9F71D-5724-4F8D-9E25-5B2D0556A71EQ34020601-F68B71D1-B1F6-42E9-ADBB-29D6DCCF684FQ34402325-467C6CD2-F973-475A-9422-65D1D3CDCC0FQ34999913-A7D077E8-ADB8-48E8-8914-B0357D81C33AQ35008028-A94DFC2B-6522-42EB-B8D0-C517DB36A1A0Q35025009-B728599E-EFAA-42F7-880F-FB5A72BD78D5Q35571452-528C129A-3FEE-4590-BE59-835D04242BF0Q35602135-ED7AE391-2295-4884-998A-B431B3211B86Q35890128-BD12BC73-E456-452E-951A-98F3E3A0EFBEQ35975142-3205AD7D-928A-4E85-958F-C24D5D7B1014Q36072292-CE26C589-77DD-48F8-AD98-1BAB589F9620Q36132797-D2A0F2D0-929C-4913-AC42-922062758290Q36172627-ABCB9CFE-8BAD-4ED0-97D3-031297ACF822Q36195093-E5B46F63-4362-418D-BB95-32131FDD6F72Q36196817-C4BC56BE-2D01-4F8A-8C18-0275ACBE0295Q36302347-317E3633-2791-4A7B-88A8-6CC81C7EFA56Q36400027-47A3B5A0-22A6-46ED-836A-3F5D2CEEA78BQ36529843-474A1929-1229-483F-A966-D1464666A62FQ36656097-580F8DFE-35D6-4F6A-95D6-DE7D1CA1B2F6Q36659339-4DBF3F08-B807-4034-A5A0-46F488CCC6F2Q36868012-6E47492C-778B-4276-9200-959A0231AC8EQ36880604-77F9F378-1016-40D9-A57B-7CF5B8F5D7E9Q37101367-1EE109AB-EC5E-43A6-B9E3-B07CF9DC87E6Q37139435-3783A23A-EB8F-436F-829D-1EB2A8631EE5Q37337359-90A9CF77-B013-4EF2-AA1D-F8476808386CQ37362739-70A9A534-4FD7-45A1-84C5-735D972E6365Q37711811-00A6695A-3E38-4162-8502-702A1ADE88BBQ37723692-7FC8EA2D-A474-4064-B1FD-75E81912EE7FQ37925133-713566FA-8784-45BE-A2DA-0FB10B3F417DQ37995872-E55ABF32-1377-4CF4-81AD-5580CB33D45C
P2860
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Evaluation of EGFR gene copy n ...... head and neck: EXTREME study.
@ast
Evaluation of EGFR gene copy n ...... head and neck: EXTREME study.
@en
Evaluation of EGFR gene copy n ...... head and neck: EXTREME study.
@nl
type
label
Evaluation of EGFR gene copy n ...... head and neck: EXTREME study.
@ast
Evaluation of EGFR gene copy n ...... head and neck: EXTREME study.
@en
Evaluation of EGFR gene copy n ...... head and neck: EXTREME study.
@nl
altLabel
Evaluation of EGFR gene copy n ...... e head and neck: EXTREME study
@en
prefLabel
Evaluation of EGFR gene copy n ...... head and neck: EXTREME study.
@ast
Evaluation of EGFR gene copy n ...... head and neck: EXTREME study.
@en
Evaluation of EGFR gene copy n ...... head and neck: EXTREME study.
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
Evaluation of EGFR gene copy n ...... head and neck: EXTREME study.
@en
P2093
D Zabolotnyy
J B Vermorken
P2860
P304
P3181
P356
10.1093/ANNONC/MDQ588
P577
2011-05-01T00:00:00Z